Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson divests its Critikon patient monitoring business to investor group led by Liberty Partners and Critikon management for undisclosed terms. Going private allows Tampa, Florida-based Critikon "to focus on our strength in vital signs monitoring, specifically non-invasive blood pressure detection and blood pressure cuffs, while improving the access to vital information for caregivers," President and CEO Gordie Nye states

You may also be interested in...

GE Medical Gains Access To DinaMap Via Critikon Purchase

GE Medical Systems' purchase of Critikon will allow it to integrate the Tampa, Florida-based firm's DinaMap non-invasive blood pressure software technology with GE's Dash line of patient monitors. The deal is expected to close by year-end.

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts